Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Biodesix (BDSX) Research & Development (2019 - 2025)

Historic Research & Development for Biodesix (BDSX) over the last 7 years, with Q3 2025 value amounting to $3.0 million.

  • Biodesix's Research & Development rose 1747.15% to $3.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $11.5 million, marking a year-over-year increase of 2779.5%. This contributed to the annual value of $9.6 million for FY2024, which is 429.52% down from last year.
  • Biodesix's Research & Development amounted to $3.0 million in Q3 2025, which was up 1747.15% from $3.3 million recorded in Q2 2025.
  • In the past 5 years, Biodesix's Research & Development registered a high of $3.6 million during Q4 2022, and its lowest value of $1.9 million during Q4 2023.
  • In the last 5 years, Biodesix's Research & Development had a median value of $3.0 million in 2022 and averaged $2.9 million.
  • In the last 5 years, Biodesix's Research & Development surged by 5771.24% in 2021 and then plummeted by 4701.26% in 2023.
  • Over the past 5 years, Biodesix's Research & Development (Quarter) stood at $2.9 million in 2021, then rose by 25.0% to $3.6 million in 2022, then plummeted by 47.01% to $1.9 million in 2023, then rose by 27.79% to $2.4 million in 2024, then increased by 23.94% to $3.0 million in 2025.
  • Its Research & Development stands at $3.0 million for Q3 2025, versus $3.3 million for Q2 2025 and $2.9 million for Q1 2025.